ChondroFiller is not available on the NHS

ChondroFiller® is not available on the NHS. As of mid-2026, no NICE technology appraisal has been published for this treatment, and it carries no NHS commissioning decision. That means a GP referral to an NHS orthopaedic department will not lead to ChondroFiller — NHS hospitals do not stock or fund it, and that position is unlikely to change in the near term. The absence of a published NICE appraisal pathway makes imminent commissioning improbable, regardless of how the evidence base develops in the interim.

This is not a comment on the treatment's clinical credentials. CE-marked Class III medical devices can be introduced through private practice without completing a NICE review, and ChondroFiller® has followed that route since its introduction to the UK. The practical consequence for patients is straightforward: access is self-funded and runs through specialist private clinics rather than through NHS waiting lists. A well-defined private pathway does exist, and it is the one covered in the sections that follow.

What ChondroFiller is and who it may suit

Classified as a CE-marked Class III medical device, ChondroFiller® is placed into the damaged joint as an ultrasound-guided outpatient injection — no general anaesthetic, no surgical incision, and no theatre admission.

The scaffold is made from purified murine-derived Type I collagen. Once injected, it self-gels within minutes, filling the defect and providing a structural matrix. The underlying mechanism is acellular matrix-induced chondrogenesis: ChondroFiller® does not deliver cartilage cells directly but instead recruits the patient's own progenitor cells — drawn from the surrounding synovium and subchondral bone — and supports their differentiation into chondrocytes. This distinguishes it from purely symptom-managing injections; the aim is to support the body's own repair processes within a defined defect, not to coat a broadly degenerate joint.

The treatment is designed for focal cartilage damage rather than widespread joint degeneration. It is not appropriate for every form of arthritis, and the clinical evidence does not support describing it as a way to 'regrow' cartilage across a whole joint. Where it is used for suitable focal defects, it has been shown to produce hyaline-like repair tissue — structurally closer to native cartilage than the fibrocartilage generated by older procedures such as microfracture. Published outcome data document meaningful functional improvement in knee patients at 12 months, with a complication rate reported at approximately zero in the manufacturer's clinical evaluation report (Version 09, April 2025).

Whether a patient is a suitable candidate depends on defect characteristics, overall joint health, and imaging findings — a judgement that requires a consultant assessment.

How to access ChondroFiller privately — without a referral

Booking a private assessment for ChondroFiller® does not require a GP letter or a referral threshold — patients can approach a specialist clinic directly. The more useful question at this stage is what to look for in a provider.

A suitable clinic should offer consultant-led assessment (not a triage call), access to diagnostic imaging capable of characterising the cartilage defect, and a treatment plan built around the imaging findings rather than a fixed menu. Defect size and location determine how many boxes of ChondroFiller® are needed — this can only be established once the relevant imaging has been reviewed, which is why any cost estimate issued before that review is provisional at best.

For patients in Lincolnshire and across the East Midlands, MSK Doctors runs consultant-led clinics in Sleaford (NG34) and Grantham (NG31). Both sites are equipped for musculoskeletal assessment and imaging, and both operate without NHS-style waiting lists or referral requirements. The typical pathway runs from an initial consultation through imaging review to a personalised treatment plan. If ChondroFiller® is not the best clinical fit for a particular patient, the consultants will say so plainly and explain what alternative may suit better.

Patients based in or near London can access the same pathway through the London Cartilage Clinic, the group's London arm. Across all sites, the approach is the same: consultant-led, evidence-informed, and honest about suitability before any treatment decision is made.

Private medical insurance — what to check before your appointment

Before contacting your insurer, it helps to have the right reference codes. ChondroFiller® treatments are billed under CCSD codes W3111 (cartilage regeneration with collagen scaffold) and W8500 (arthroscopy); citing these codes specifically — rather than a general description of the procedure — gives the insurer's pre-authorisation team a precise line to search against their fee schedules.

Coverage is neither guaranteed nor categorically ruled out. Standard PMI policies do not include ChondroFiller® as a routine benefit, but pre-authorisation has been granted on a case-by-case basis with Bupa, Aviva, and WPA, among others (guidance current to October 2025). Whether a given policy covers the treatment depends on the specific policy wording, the clinical justification submitted, and the insurer's own review process at the time of the application.

Verbal confirmation from an insurer call-handler carries no contractual weight. Written pre-authorisation — a reference number tied to the specific procedure and provider — must be in hand before treatment begins. If approval is declined or the policy does not extend to ChondroFiller®, patients proceeding on a self-funded basis can request an itemised invoice from the clinic and submit it independently to their insurer; some policies will reimburse part of the cost even without prior authorisation, though this is not predictable in advance.

A consultant assessment is a sensible first step regardless of funding route: the insurer's pre-authorisation team will need a clinical letter, imaging findings, and a treatment plan before making any decision.

Questions to ask your consultant before committing

A short list of focused questions, raised before any commitment is made, can clarify more than a lengthy follow-up correspondence.

First, ask that your imaging is reviewed before a cost estimate is issued. Without the scan, a price is provisional; the consultation should inform the quote, not the other way round.

Second, ask about what to expect during recovery. The ultrasound-guided injection pathway involves a short rest period before returning to normal movement; return-to-sport timelines vary according to the joint involved and the extent of the defect, so ask your consultant to give you a realistic range specific to your situation.

Third, ask whether ChondroFiller® would affect your options if you eventually need a joint replacement. Current evidence does not indicate that prior treatment with ChondroFiller® complicates subsequent joint replacement surgery — but this is worth confirming with your consultant in the context of your own imaging and history.

Fourth, ask whether the same consultant who assesses you will also be the one administering the treatment. Continuity between assessment and delivery is a legitimate quality consideration, and clinics that separate the two functions are worth questioning directly on this point.

Finally, if cost is a factor, ask for a clear breakdown of what the guide cost includes — consultation, imaging review, the treatment itself, any follow-up appointments — so there are no unexpected additions later. A transparent itemised estimate is a reasonable thing to request before any booking is confirmed.

What the evidence currently shows — and where thegaps are

The clinical picture is encouraging in the short term, but the evidence base carries a structural limitation patients should understand before committing: almost all available outcome data originates from the manufacturer's own clinical evaluation programme (CER version 09, April 2025). The 30-point functional improvement at 12 months documented in knee patients and the complaint rate of approximately 0.06% are meaningful figures — but they have not yet been independently verified through a UK health technology assessment, and the longest published follow-up extends to around two years. No NICE appraisal has been initiated.

Where comparison with established alternatives is possible, the distinction from microfracture is clinically significant. Microfracture is generally limited to smaller defects and produces fibrocartilage — a mechanically inferior tissue — whereas ChondroFiller®'s acellular scaffold supports the formation of hyaline-like tissue more closely resembling native articular cartilage. That is a meaningful difference in principle; long-term outcome data to confirm the durability advantage remains limited in practice.

Reoperation rates of approximately 3–8% based on the same 2025 evaluation report suggest that the treatment does not uniformly resolve every case, and individual responses vary. Insurance outcomes remain policy- and case-specific and carry no blanket guarantee.

Taken together, the evidence supports cautious optimism for patients with suitable focal defects — a low risk profile and a positive functional trajectory at the evidence horizon available. What it does not support is reading this as a cure or a definitive long-term solution. Patients making this decision are working with promising early data from a single evidence source, and that context belongs in any honest conversation with a specialist.